An Integrated Approach To Support ADC Programs From Concept To Clinical Material
As the ADC industry moves forward, we need to look at the development and manufacturing process from an end-to-end perspective. How does every stage fit together to make the final ADC, instead of segmenting the process into mAb production separate from drug-linker manufacturing, apart from the conjugation?
Our integrated approach can help you interrogate raw materials early on, so you pick the ones that make the best ADC, not just the most material.
As a result, we can provide seamless characterization from the mAb raw material to the final ADC construct.
In this webinar you will learn:
- About the impact of raw material characterization on conjugation chemistry
- Examples where incomplete characterization delayed timelines
- The importance of an integrated offering from early development through manufacturing
Daniel Galbraith, PhD, Head of Product Characterization Strategy
Jeffery Carroll, Group Leader, Process and Analytical Development
- Virtual ADC & Bioconjugation Symposium – December 2-3, 2020 - November 2, 2020